Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Grows By 82.3%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 26,800 shares, a growth of 82.3% from the February 28th total of 14,700 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 17,700 shares, the short-interest ratio is currently 1.5 days.

PharmaCyte Biotech Price Performance

Shares of PharmaCyte Biotech stock opened at $1.32 on Monday. The company’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.69. PharmaCyte Biotech has a 1-year low of $1.29 and a 1-year high of $2.55. The stock has a market capitalization of $9.06 million, a PE ratio of 2.49 and a beta of -0.25.

PharmaCyte Biotech (NASDAQ:PMCB) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.10) earnings per share for the quarter.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.